SOTIO’s SOT106 ADC Gets FDA Fast Track for Sarcoma
PRAGUE, Basel & Boston, Aug. 26, 2026 SOTIO Biotech announced that the U.S. Food and Drug Administration (FDA) has...
Osteosarcoma
Advertisement
Junshi Expands Toripalimab to Stage II-III NSCLC
SHANGHAI, China, July 21, 2026 Junshi Biosciences has announced that the National Medical Products Administration (NMPA) has accepted a...
Healx Doses First Patient in HLX-4310 Phase 1/2 Trial
CAMBRIDGE, UK, July 22, 2026 Healx, an AI-powered clinical-stage biotechnology company, has announced that the first patient has been...
OS Therapies Advances OST-HER2 Ahead of ASCO 2026 Presentation
NEW YORK and ROCKVILLE, Md., May 29, 2026 OS Therapies announced the publication of four scientific articles focused on...
OS Therapies Secures EMA Review for OST-HER2 Drug
NEW YORK, New York, April 30, 2026 OS Therapies announced that the European Medicines Agency (EMA) has initiated a...
Advertisements
OS Therapies Advances OST-HER2 Toward FDA Approval
NEW YORK, March 31, 2026 — OS Therapies, Inc a clinical-stage oncology company specializing in listeria-based cancer immunotherapies, has...
OS Therapies Advances OST-HER2 Toward Phase 3 Trial
New York, March 27, 2026 OS Therapies has achieved a significant regulatory milestone by securing meetings with multiple global...
OST-HER2 Regulatory Progress Advances Osteosarcoma Care
NEW YORK, NEW YORK, UNITED STATES — February 17, 2026 OS Therapies has announced a major global regulatory update...
OS Therapies Gains Key FDA & EMA Milestones for OST-HER2 Immunotherapy
NEW YORK, NY — December 5, 2025 — OS Therapies Inc. announced two major regulatory milestones advancing its lead...
OS Therapies Accelerates OST-HER2 Toward 2026 BLA with Strong Q3 Progress
Dateline: November 17, 2025 — New York, NYOS Therapies reported its third-quarter 2025 financial results and issued a comprehensive...
Advertisement
